Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors.

Nicolas Isambert (1, 2, 3, 4) , Pierre Fumoleau (2, 4) , Catherine Paul (1, 3, 4) , Christophe Ferrand (1) , Sylvie Zanetta (2) , Jacques Bauer (5) , Kevin Ragot (4) , Gérard Lizard (4) , Jean-François Jeannin (1, 3, 4) , Marc Bardou (1, 4, 6)

1 CIC-P803 - Centre d'Investigation Clinique 1432 (Dijon) - Module Plurithématique : Périnatalité Cancérologie Handicap et Ophtalmologie
2 UNICANCER/CRLCC-CGFL - Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon]
3 LIIC - Laboratoire d'Immunologie et Immunothérapie des Cancers
4 LNC - Lipides - Nutrition - Cancer (U866)
5 Research & Development
6 Pharmacie [CHU de Dijon]

BACKGROUND: Lipids A, the lipophilic partial structure of lipopolysaccharides, induce regression of several tumor types in animal models. Rather than exerting direct cytotoxic effect, these compounds trigger the immune system which in turn stimulates secretion of cytokines, and activates the inducible nitric oxide synthase, as well as immune cell infiltration of tumors. OM-174 is an analogue of lipid A with dual action on toll-like receptors 2 and 4. In an experimental model of peritoneal carcinomatosis induced in BDIX rats by intraperitoneal injection of syngeneic PROb colon cancer cells, it induced a complete regression of tumors. The present phase I trial was conducted to determine the maximum tolerated dose, the recommended phase II dose and biological response associated with OM-174 administered as intravenous infusion. METHODS: Patients received OM-174 twice weekly for a total of 5, 10 or 15 injections of either 600, 800 or 1000 mug/m2. Blood samples for pharmacokinetic analysis and cytokine dosages were collected. NK cells activity and toll-like receptors 4 polymorphism analysis were also performed. RESULTS: Seventeen patients were included. The highest dose administered was 1000 mug/m2 repeated in 15 injections. The most common toxicities were a chills, fever, nausea/vomiting, diarrhea, fatigue and headache. No patient experienced haematological side effects. As no dose limiting toxicity was observed, despite a grade 3 respiratory complication, the maximal tolerated dose and recommended dose were not established. Three patients exhibited disease stabilization with a mean duration of 4 months. Pharmacokinetic profile of OM-174 was characterized by a low distribution volume and clearance. Analysis of TLR 4 polymorphysm showed that most (16/17) patients carried the wild type alleles. A progressive increase in NK cell number and activity was observed only in patients receiving 1000 mug/m2 of OM-174. A peak of IL 8 and IL-10 concentrations were observed after each OM-174 injection. Peaks of TNF-alpha and IL-6 concentrations were detected after the first infusion and decreased progressively suggesting tolerance. CONCLUSION: OM-174 therapy was well tolerated at biologically active concentrations. Whereas the recommended dose was not determined, further studies are planned in combination with chemotherapy as animal models suggest a strong synergistic antitumor effect.Trial registration: NCT01800812 (ClinicalTrials.gov Identifier).

Keywords: Immune response; OM-174; Lipid A analogue; Refractory solid tumors; Phase I

Domains: Cancer

Nicolas Isambert, Pierre Fumoleau, Catherine Paul, Christophe Ferrand, Sylvie Zanetta, et al.. Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors.. BMC Cancer, 2013, 13 (1), pp.172. ⟨10.1186/1471-2407-13-172⟩. ⟨inserm-00813522⟩